相关实验视频
Updated: Jun 4, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
糖尿病管理的草药方法:药理机制和Omics驱动的发现
Debajyoti Roy1,2, Maitrayee Ghosh1,3, Naresh Kumar Rangra4
1Faculty of Pharmacy, CV Raman Global University, Bhubaneswar, Odisha, India.
这篇评论探讨了像Anacardium occidentale和Allium sativum这样的草药,用于治疗糖尿病及其并发症. 它强调了它们改善胰岛素敏感性和减少氧化应激的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
- 草药是一种草药.
背景情况:
- 糖尿病是一种慢性代谢障碍,其特点是高血糖和胰岛素抵抗.
- 糖尿病并发症包括病,神经病,心血管疾病和视网膜病变.
- 草药在治疗糖尿病症状和并发症方面显示出潜在的潜力.
研究的目的:
- 为了评估Anacardium occidentale,Allium sativum,Urtica dioica和Cinnamomum zeylanicum的药理性质. 为了评估Anacardium occidentale,Allium sativum,Urtica dioica和Cinnamomum zeylanicum的药理性质. 为了评估Anacardium occidentale,Allium sativum,Urtica dioica和Cinnamomum zeylanicum的药理性质. 为了评估Anacardium occidentale,Allium sativum,Urtica dioica和Cinnamomum zeylanicum的药理性质.
- 检查生物活性植物化学物质如奎尔素,白醇,柏柏林和表甲基酸盐 (EGCG) 的作用机制.
- 探索多奥米克技术在发现糖尿病新草药治疗候选者的作用.
主要方法:
- 关于植物疗法及其生物活性化合物的文献综述.
- 对药理机制的分析,包括胰岛素敏感化,碳水化合物水解和氧化应激减轻.
- 在草药学中讨论基因组学,蛋白质组学,代谢组学和转录组学的整合.
主要成果:
- 精选的植物疗法和植物化学物质显示出改善胰岛素敏感性和减轻糖尿病并发症的潜力.
- 机制包括增强胰岛素分泌,抑制碳水化合物消化,减少氧化应激.
- 多omics技术为识别和验证草药治疗候选人提供了先进的方法.
结论:
- 草药是糖尿病管理和并发症预防的有希望的途径.
- 进一步进行高质量的临床试验至关重要,以验证这些化合物的有效性和安全性.
- 改进的研究设计,生物标志物选择和安全性分析对于在临床实践中推进草药疗法至关重要.
更多相关视频
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
相关概念视频
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...